Monopar Commences Phase 1 Study for Innovative Cancer Imaging Agent MNPR-101-Zr

Monopar Therapeutics, a biopharmaceutical firm listed on Nasdaq as MNPR, has initiated a Phase 1 clinical trial for a novel imaging agent, MNPR-101-Zr, which is designed to target advanced cancers. The agent is a conjugate of MNPR-101 with zirconium-89 and is specifically aimed at the urokinase plasminogen activator receptor (uPAR), a protein found in various tumor types such as pancreatic, breast, colorectal, and bladder cancers. 

The clinical trial is open for patient recruitment at the Melbourne Theranostic Innovation Centre (MTIC) in Australia, under the direction of Professor Rodney Hicks, a renowned expert in radiopharmaceuticals. The study will utilize the Siemens Biograph Vision Quadra, an advanced PET/CT scanner, to assess the imaging capabilities of MNPR-101-Zr in patients. The trial's primary focus is on evaluating the safety and dosimetry of the imaging agent in up to 12 patients with advanced cancer. Encouraging preclinical data have demonstrated the agent's specificity and sustained uptake in human cancer models. Monopar has also reported positive preclinical findings regarding the anti-tumor efficacy of MNPR-101 when linked with therapeutic radioisotopes. The company intends to expand the study or initiate a new one to test the therapeutic potential of MNPR-101 with a radioisotope like Ac-225, pending positive results from the current trial. 

Monopar's CEO, Dr. Chandler Robinson, expressed enthusiasm for the trial, highlighting the promising preclinical outcomes in challenging cancers and the potential of their radiopharmaceutical program to target and eradicate uPAR-expressing tumors. More details on the MNPR-101-Zr trial can be found on www.ClinicalTrials.gov with the identifier NCT06337084. Monopar Therapeutics is engaged in developing innovative cancer treatments with a pipeline that includes MNPR-101 for radiopharmaceutical applications, camsirubicin for soft tissue sarcoma, and an early-stage camsirubicin analog, MNPR-202. For further information, visit www.monopartx.com and ir.monopartx.com/presentations. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!